← Leaderboards
Vickram Ramkumar
Southern Illinois University Sch Of Med
$4,254,862
Attributed
$4,254,862
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $728.9K · FY2008–21$1M$750K$500K$250K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,254,862 · 5
By mechanism
R01$3,383,362 · 2
R15$871,500 · 3
Top collaborators
No co-investigators on record.
Most similar at Southern Illinois University Sch Of Med
Same institution · by research overlap
- Michael J. Brenner$1,168,465
- Debashree Mukherjea$654,636
- Leonard P Rybak$5,077,862
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsHearing ImpairmentNadph OxidaseGenerationsBaseMediatingReactive Oxygen SpeciesCisplatinCellsAntineoplastic AgentsSourceCell DeathInflammatoryRattusPathway InteractionsInflammationOtotoxicityPlatinumEffective TherapyApoptosisNephrotoxicityCancer PatientMalignant NeoplasmsCancer Cell
Grant awards (13)
Oral Epigallocatechin Gallate (EGCG) for Treatment of Cisplatin Ototoxicity$367,187
R01 · FY2021 · DC · contact PI
Oral Epigallocatechin Gallate (EGCG) for Treatment of Alzheimer's Disease Induced Hearing Loss$361,744
R01 · FY2021 · DC · contact PI
Oral Epigallocatechin Gallate (EGCG) for Treatment of Cisplatin Ototoxicity$361,208
R01 · FY2020 · DC · contact PI
Oral Epigallocatechin Gallate (EGCG) for Treatment of Cisplatin Ototoxicity$392,079
R01 · FY2019 · DC · contact PI
Oral Epigallocatechin Gallate (EGCG) for Treatment of Cisplatin Ototoxicity$403,954
R01 · FY2018 · DC · contact PI
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity$301,907
R01 · FY2017 · CA · contact PI
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity$302,080
R01 · FY2016 · CA · contact PI
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity$301,918
R01 · FY2015 · CA · contact PI
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity$291,855
R01 · FY2014 · CA · contact PI
Transplatin: A Novel Agent to Mitigate Cisplatin Toxicity$299,430
R01 · FY2013 · CA · contact PI
Targeting Inflammation for the Amelioration of Cisplatin-Hearing Loss$436,500
R15 · FY2011 · DC · contact PI
Role of adenosine A3 receptor in suppressing prostate cancer$218,250
R15 · FY2008 · CA · contact PI
Nerve Growth Factor and Transient Receptor Potential (TRPV1) Channel in Diabetic$216,750
R15 · FY2008 · NS · contact PI